New Delhi, Feb 23 (PTI) Sun Pharma Advanced Research Company Ltd on Tuesday said the USFDA has ruled against its appeal related to Taclantis, its under development product for treatment of breast cancer.

The Office of New Drugs (OND) of the US Food and Drug Administration (FDA) has denied the company's appeal of the Complete Response Letter (CRL) in relation to the New Drug Application (NDA) for Taclantis, Sun Pharma Advanced Research Company (SPARC) said in a regulatory filing.

In its letter, the OND requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis NDA, it added.

The company will review FDA's response and decide on appropriate next steps soon, SPARC noted.

As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.

On July 1, 2019, the company had announced that the USFDA had accepted for review SPARC's NDA for Taclantis.

The company's NDA filing was based on successful demonstration of clinical bioequivalence of Taclantis with Abraxane and associated clinical safety data.

Abraxane is indicated for treatment of breast cancer, lung cancer, among others.

In 2017, USFDA had denied approval to SPARC's new drug application for Elepsia XR, an anti-epileptic drug.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)